Site Map | Legal Policy | Privacy Policy

 

Corporate Governance

Ligand effected the sale of all its commercial products and as of February, 2007 changed its business strategy to focus on a targeted internal research and development effort.

Title  
Annual Declaration of Compliance  
Code of Conduct and Ethics Policy  



Corporate Charters

Document  
Audit Committee Charter  
Compensation Committee Charter  
Nominating Committee Charter  


News

Ligand Pharmaceuticals Announces First Quarter Results

Ligand Initiates Phase II Trial with LGD-4665 in Idiopathic .......

Upcoming Events

Q1 2008 Ligand Pharmaceuticals Incorporated Earnings Confere...

Susquehanna Financial Group Second Annual SIGnificant Option...

Q4 2007 Ligand Pharmaceuticals Incorporated Earnings Confere...

Investor Relations|News|Presentations & Events|SEC Documents|
Corporate Governance|Email Alerts
LGND - (NASD)
$3.39   - 0.03